This Phase II trial, called NC001 or New Combination 1, tests the new TB drug candidates PA-824 and moxifloxacin in combination with pyrazinamide,This Phase II which show potential to shorten treatment time for virtually all tuberculosis patients and harmonize the treatment of DS-TB and MDR-TB-- an emerging global health threat. Both new compounds are being developed by the non profit organization TB Alliance, in partnership with Bayer HealthCare AG. The trials are going to begin at two centres in South Africa—one of the highest TB burden countries.
There is a desperate need for better and faster acting TB treatments to address today’s growing TB pandemic, which knows no boundary, and kills nearly 2 million people each year. It is the third leading cause of death among women of child-bearing age in the developing world and the leading killer of people with HIV/AIDS. Due to the length and complexity of the current TB treatment, many patients are unable to complete their treatment, leading to increasing drug resistance, an emerging global health threat. Hence this new initiative of TB Alliance, aptly called
This research approach is being championed by the
“We need more than a new drug to eradicate TB—we need entirely new regimens of TB drugs,” said Mel Spigelman, M.D., President and Chief Executive Officer, TB Alliance. “The potential to offer a single regimen to treat both drug-sensitive and multidrug-resistant TB represents a monumental advance in the treatment of patients worldwide, and a tremendous step toward simplifying the delivery of TB treatment globally.”
“New and powerful drugs to combat TB and MDR-TB are essential to achieving TB control goals outlined in the Global Plan to Stop TB 2011-2015 and ultimately to eliminate TB,” said Mario Raviglione, M.D., Director of the World Health Organization’s Stop TB Department. “It is extremely encouraging to see a growing pipeline of TB drug candidates that may revolutionize TB care and committed sponsors moving with speed and efficiency towards new regimens.”
Francis Apina, a TB activist from Kenya, rightly emphasized upon the meaningful participation of the community in promoting research for new and simpler drug regimens from the grass roots level, as they are the biggest stakeholder in the fight against tuberculosis.
It is hoped that the new drug regimens will not only make TB treatment simpler, but also more cost effective, so that they reach the most vulnerable sections of society, and do not remain the property of a select few.
Shobha Shukla - CNS
(The author is the Editor of Citizen News Service (CNS) and also serves as the Director of CNS Diabetes Media Initiative (CNS-DMI). She has worked earlier with State Planning Institute, UP. She is supported by the Stop TB Partnership to write from the 41st Union World Conference on Lung Health, Berlin, Germany (11-15 November 2010). Email: email@example.com, website: www.citizen-news.org)
The Asian Tribune, Sri Lanka/Thailand
News Blaze News, California, USA
Now Public News, India
Earth Times, Berlin, Germany
Citizen News Service (CNS), India/Thailand
Elites TV News, USA
Sun Herald News